AOD-9604 is a lab-made peptide built from the tail end of human growth hormone. Growth hormone does many things — one of them is helping the body burn fat. Scientists found that a small piece from the end of the hormone seemed to carry the fat-burning part without the rest. AOD-9604 is an engineered version of that piece, and it was developed specifically as a weight-loss drug. Here is the part vendor pages skip: its biggest human trial did not work.
In plain terms: exciting fat-loss results in mice, but the human obesity trial missed its target.
What it is
Human growth hormone is a 191-amino-acid protein. Back in the 1990s, researchers at Monash University narrowed its fat-burning ("lipolytic") activity down to the last stretch of the molecule — amino acids 176 to 1911. AOD-9604 is that 16-amino-acid fragment with one extra building block, the amino acid tyrosine, added at the front to make it more stable. The name AOD stands for "Anti-Obesity Drug" — a clue to exactly what it was designed to be.
Crucially, AOD-9604 was engineered to keep the fat-burning part and drop the rest. Full growth hormone can raise blood sugar and drive tissue growth; in studies AOD-9604 did neither — it did not compete for the growth-hormone receptor and did not change IGF-1 levels or insulin sensitivity12.
How it is thought to work
The proposed mechanism is lipolysis — the breakdown of stored fat. In mouse studies, AOD-9604 increased the activity of the beta-3 adrenergic receptor (beta-3-AR), the main "burn fat" switch on fat cells2.
The cleanest evidence for that mechanism came from a knockout experiment. Researchers gave AOD-9604 to normal obese mice and to mice genetically engineered to lack the beta-3 receptor. In normal mice it reduced body fat; in the knockout mice the effect disappeared2. That is a strong way to prove a mechanism — remove the receptor, and the drug stops working.
In plain terms: in mice, it appears to flip the fat-burning switch on fat cells. Important caveat — this was shown in mice and cells, so treat it as a mechanism, not a proven human effect.
What the studies actually found
Here is where honesty matters most, because the animal and human stories point in different directions. Note the model in each row:
| Study | Model | Key result | Year |
|---|---|---|---|
| Ng et al.1 | Mouse + cell studies | Identified the 176-191 lipolytic domain; the fragment burned fat like growth hormone but without raising blood sugar | 2000 |
| Heffernan et al.2 | Obese mice + beta-3-AR knockout mice | Reduced body fat via the beta-3 receptor; the effect vanished in mice lacking that receptor | 2001 |
| Stier et al. — human safety review3 | Human (6 trials, 900+ people) | Consistently safe and well tolerated, with no adverse effect on blood sugar; but the largest efficacy trial did not beat placebo on weight loss | 2013 |
Read the bottom row carefully. AOD-9604 was studied in humans more than most peptides in this space — six clinical trials involving over 900 participants3. Across those, it looked safe. But safe is not the same as effective. Its largest efficacy study — a phase-2b obesity trial in several hundred adults over 24 weeks — did not separate from placebo on the primary weight-loss endpoint at any dose tested, and the anti-obesity drug development program was subsequently discontinued.
The honest catch: safe, but the weight-loss trial failed
This is the single most important thing to understand about AOD-9604, and it is the opposite of how it is usually marketed:
- What held up: a clear fat-burning mechanism in mice, and a reassuring human safety profile23.
- What did not: proof that it produces meaningful weight loss in people. The primary endpoint of its largest human obesity trial was not met3.
So the phrase "AOD-9604 is a proven fat-loss peptide" is misleading. Its fat-loss evidence is strong in mice and weak-to-absent in the human efficacy data that actually tested that claim.
Regulatory status
AOD-9604 is not an approved weight-loss medicine. After its obesity drug program was dropped, it was explored as a nutraceutical-type ingredient and for other uses, but it has no drug approval as an obesity treatment. This page takes no position on sourcing and never discusses where to obtain anything.
Latest research
- The human safety record remains its most solid finding — multiple trials, consistently well tolerated, no negative effect on blood sugar3.
- The efficacy gap is the durable story: the mouse fat-loss results never translated into a positive human obesity trial, which is why it is not a weight-loss drug today3.
- Interest has since shifted toward possible non-weight uses (such as cartilage and joint research), but those are early and separate from the fat-loss claim. We update this section as new studies land.
The short version
AOD-9604 is a modified growth-hormone fragment (the 176-191 region plus a tyrosine) built to burn fat without growth hormone's blood-sugar effects. In mice it convincingly triggered fat breakdown through the beta-3 receptor. But it was tested extensively in humans and — while safe — its largest obesity trial missed its primary endpoint, and the drug program was dropped. It is a research compound, not a proven fat-loss medicine. Its close relative is HGH Fragment 176-191; educational overview only.